Erste Studie zur Eskalation der menschlichen Dosis zur Bewertung der Sicherheit des TheraSphere Prostate Cancer (PCa)-Geräts (VOYAGER)
Eine frühe Machbarkeitsstudie zur Bewertung der Sicherheit des TheraSphere Prostate Cancer (PCa)-Geräts bei Patienten mit klinisch lokalisiertem Prostatakrebs
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
TheraSphere™ Y-90 Glass Microspheres are a targeted cancer therapy consisting of tiny glass beads containing radioactive Yttrium-90 (Y-90), which are injected directly into the blood vessel feeding the tumor through a microcatheter using advanced imaging guidance. The glass microspheres enter the tumor's blood supply, lodge within the blood vessels feeding the tumor, and release radiation to the tumor. The radiation works to destroy the tumor cells from within, thus limiting radiation exposure to surrounding normal tissues, a process referred to as selective internal radiation therapy (SIRT).
This study aims to investigate the maximum safe radiation dose of TheraSphere Prostate Cancer (PCa) device that can be delivered in patients with clinically localized prostate cancer. The study will also evaluate the full safety profile, technical feasibility, efficacy, and quality of life metrics of the TheraSphere PCa device.
Participants will be asked to complete the following:
- At least two image-guided visits, including a mapping assessment (without Technetium Tc albumin aggregated [Tc-MAA]) prior to treatment
- One treatment visit, including image-guided assessments
- Fifteen post-treatment follow-up visits for a total of approximately 20 visits over the 5-year study period
Note: the VOYAGER Study is a staged investigational device exemption (IDE) study; therefore, the full enrollment of 21 to 36 subjects is subject to FDA approval following safety review of the first 10 subjects enrolled.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern Memorial Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Subject has ability to comprehend and willingness to sign and date the IRB-approved study informed consent form (ICF), and to comply with the study testing, procedures, and follow-up schedule.
-
Histologic confirmation of adenocarcinoma of the prostate by MR-fusion biopsy. Referral biopsy for eligibility must be completed between 180 days and 6 weeks prior to mapping procedure.
-
Subject with favorable intermediate risk clinically localized prostate cancer defined per NCCN Guidelines version 3.2022 as follows:
-
Favorable intermediate-risk has all the following:
-
i. One Intermediate Risk Factor (IRF):
- cT2b-cT2c
- Grade Group 2 or 3
- PSA 10-20 ng/mL
-
ii. Grade Group 1 or 2
-
iii. <50% biopsy cores positive (e.g., <6 of 12 cores)
-
-
Staging MRI must confirm American Joint Committee on Cancer (AJCC, 8th edition) stage T1, T2a, T2b or T2c.
-
Whole prostate gland volume ≥ 60 cc (measured on MRI)
-
International Prostate Score Symptom (I-PSS) ≤ 18
-
Estimated life expectancy of >5 years according to NCCN guideline's tools (NCCN v03.2022) who has declined or is ineligible for Standard of Care treatments (observation, active surveillance, surgery, and radiation therapies [brachytherapy/external beam radiation therapy])
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
-
Angiographic inclusion criteria:
- a. Type I to IV prostate artery origins on both hemiglands.1
- b. No evidence of procedure limiting vascular abnormalities (aneurysms, stenosis, shunt, fistula, occlusion) or morphologic asymmetric single prostate artery on either side (hemigland)
- c. Bilaterally accessible solitary prostatic arteries.
- d. Complete perfusion of the prostate gland via a single dominant vessel for each hemigland
-
Have adequate organ and bone marrow function within 30 days prior to index procedure, as defined below:
- a. International Normalized Ratio (INR) ≤ 1.2 (in absence of anticoagulation)
- b. Platelets ≥ 75,000/L
- c. GFR ≥ 40 mL/min/1.73m2
- d. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
- e. Hemoglobin (Hgb) ≥ 9.0 g/dL (Note: the use of transfusion or other intervention to achieve adequate bone marrow function is acceptable
- f. ALT/AST ≤ 5 x upper limit of normal (ULN)
- g. Bilirubin ≤ 2 mg/dL
-
Patients with known Human Immunodeficiency Virus (HIV) infection are eligible with well controlled HIV infection, no current or previous AIDS-related complications and CD4+ T-cell (CD4+) counts ≥ 350 cells/uL
Exclusion Criteria:
-
Direct evidence of regional or distant metastases after appropriate staging studies per NCCN guidelines (v03.2022)
-
Histological evidence of intraductal features
-
Previous treatments (pelvic radiotherapy, surgery, prostate artery embolization [PAE], transurethral resection of the prostate [TURP] or previous/ planned hormonal therapy
-
History of Crohn's Disease, ulcerative colitis, or ataxia telangiectasia, current gross haematuria, or current urinary catheter
-
Subjects with ongoing urinary tract infection, prostate abscess, prostatitis, or neurogenic bladder
-
Prior significant rectal surgery (haemorrhoidectomy is acceptable)
-
Prior invasive malignancy unless disease free for a minimum of 3 years. Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease
-
Hip prosthesis
-
Medical contraindication to undergo contrast-enhanced angiography, CT scan and magnetic resonance imaging (MRI), or arterial catheterization, or known history of hypersensitivity reactions to iodinated and gadolinium-based contrast product
-
Angiographic exclusion criteria:
- a. Perfusion to tissues outside the Planning Target Volume (PTV) that cannot be corrected by placement of the catheter distal to collateral vessels or the application of standard angiographic techniques, such as coil embolization
- b. Type V prostatic artery origin on either side
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: TheraSphere PCa Dose Escalation
Participants will be treated in cohorts of three across three sequential dose levels:
|
Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Maximum tolerated radiation dose of TheraSphere PCa
Zeitfenster: Through 90 days post-treatment
|
• The Maximum Tolerated Dose (MTD) of Yttrium-90 Glass Microspheres (TheraSphere™ PCa) is based on rate of dose limiting toxicity (DLT) through 90 days, defined as any ≥ grade 3 adverse event (AE) according to CTCAE v.5 |
Through 90 days post-treatment
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of adverse events (AEs)
Zeitfenster: Through 5 years post-treatment (acute ≤ 90 days and late > 90 days)
|
The following AEs/SAEs will be assessed in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0:
|
Through 5 years post-treatment (acute ≤ 90 days and late > 90 days)
|
|
Rate of success of delivering intended dose
Zeitfenster: Immediately post-treatment
|
• The ability to deliver the intended TheraSphere PCa absorbed dose (+/- 20%) to the treatment volume based on post-treatment PET derived absorbed dose. |
Immediately post-treatment
|
|
Recurrence Free Survival
Zeitfenster: Through 5 years post-treatment
|
• Biochemical Recurrence Free Survival (bRFS) based on PSA according to the Phoenix criteria (RTOG-ASTRO definition). Biochemical recurrence of prostate cancer after curative treatment is defined as a PSA rise of ≥ 2 ng/mL above the post-treatment nadir. |
Through 5 years post-treatment
|
|
Progression free survival (PFS)
Zeitfenster: Through 5 years post-treatment
|
• Progression free survival (PFS) and local progression free survival (LPFS), defined as time from inclusion until one of the following events, whichever comes first: biochemical progression (Phoenix criteria) or clinical progression. |
Through 5 years post-treatment
|
|
Prostate cancer specific survival
Zeitfenster: Through 5 years post-treatment
|
• Prostate cancer specific survival will be measured as the number of days between treatment with TheraSphere PCa and death by prostate cancer. |
Through 5 years post-treatment
|
|
Overall survival (OS)
Zeitfenster: Through 5 years post-treatment
|
• OS will be measured as the number of days between treatment with TheraSphere PCa and death by any cause. |
Through 5 years post-treatment
|
|
Rate of subsequent prostate anticancer treatment
Zeitfenster: Through 5 years post-treatment
|
• A summary table with number of subjects (%) who received subsequent definitive or systematic therapy and type of therapies received will be presented. |
Through 5 years post-treatment
|
|
Rate of histopathological recurrence
Zeitfenster: Through 5 years post-treatment
|
• Rate of recurrence based on histopathological assessment of prostate MR/US-fusion biopsy in patients with evidence of progression. |
Through 5 years post-treatment
|
|
Quality of Life (QoL) measured by EPIC-26
Zeitfenster: Through 5 years post-treatment
|
• Change from baseline measured through Expanded Prostate Cancer Index Composite (EPIC-26). |
Through 5 years post-treatment
|
|
Quality of Life (QoL) measured by MSHQ
Zeitfenster: Through 5 years post-treatment
|
• Change from baseline measured through Male Sexual Health Questionnaire (MSHQ). |
Through 5 years post-treatment
|
|
Quality of Life (QoL) measured by I-PSS
Zeitfenster: Through 5 years post-treatment
|
• Change from baseline measured through International Prostate Symptom Score (I-PSS). |
Through 5 years post-treatment
|
|
Maximum urinary flow (Qmax)
Zeitfenster: Through 5 years post-treatment
|
• Change from baseline |
Through 5 years post-treatment
|
|
Post-void residual (PVR) urine test
Zeitfenster: Through 5 years post-treatment
|
• Change from baseline |
Through 5 years post-treatment
|
|
Dose Distribution
Zeitfenster: Through one-week post-treatment
|
• Dose Volume Histogram (DVH) and evaluation of D90 from post-treatment Y90 PET-MRI/CT. |
Through one-week post-treatment
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Prostatic imaging assessment
Zeitfenster: Through 5 years post-treatment
|
• Qualitative analysis of multi-parametric MRI (mp-MRI) and PI-RADS score |
Through 5 years post-treatment
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Samdeep Mouli, M.D., M.S., Northwestern Medical Hospital
- Hauptermittler: Mark Hurwitz, MD, Westchester Medical Center
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Mouli SK, Raiter S, Harris K, Mylarapu A, Burks M, Li W, Gordon AC, Khan A, Matsumoto M, Bailey KL, Pasciak AS, Manupipatpong S, Weiss CR, Casalino D, Miller FH, Gates VL, Hohlastos E, Lewandowski RJ, Kim DH, Dreher MR, Salem R. Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation. J Vasc Interv Radiol. 2021 Aug;32(8):1103-1112.e12. doi: 10.1016/j.jvir.2021.01.282. Epub 2021 Apr 9.
- Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res. 2018 Oct 15;24(20):4921-4930. doi: 10.1158/1078-0432.CCR-18-0246. Epub 2018 May 16.
- Meiselman S, Thomas MA, Giardina JD, Zheleznyak A, Thorek DLJ, Malone CD. Advances in Radioembolization for Liver Cancer. J Vasc Interv Radiol. 2025 Dec;36(12):1876-1881. doi: 10.1016/j.jvir.2025.07.018.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- S2493
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .